tiprankstipranks
Trending News
More News >

Celadon Pharmaceuticals Plans AIM Delisting and Privatization

Story Highlights
Celadon Pharmaceuticals Plans AIM Delisting and Privatization

Don’t Miss TipRanks’ Half-Year Sale

Celadon Pharmaceuticals PLC ( (GB:CEL) ) has issued an update.

Celadon Pharmaceuticals Plc has announced its intention to seek shareholder approval for the cancellation of its Ordinary Shares from trading on AIM, effective 8 August 2025, and to re-register as a private limited company. This strategic move is considered by the company’s CEO to be in the best interest of the company and its shareholders, aiming to streamline operations and potentially enhance its market positioning. A general meeting is scheduled for 28 July 2025 to discuss these proposals, which, if approved, could impact shareholder trading opportunities and the company’s future operational structure.

More about Celadon Pharmaceuticals PLC

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specializing in the development, production, and sale of cannabis-based medicines. The company focuses on improving the quality of life for chronic pain sufferers and exploring cannabis-based treatments for conditions like autism. It operates a large EU-GMP approved facility in the UK for cultivation, extraction, and research, and holds a Home Office license for commercial supply of pharmaceutical-grade cannabis products.

Average Trading Volume: 165,388

Technical Sentiment Signal: Sell

Current Market Cap: £7.92M

Find detailed analytics on CEL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1